Formulation and Evaluation of Atenolol Nanocrystals Using 3(2) Full Factorial Design

Author(s): Rupa Mazumder, Swarnali Das Paul*

Journal Name: Nanoscience & Nanotechnology-Asia

Volume 10 , Issue 3 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Atenolol is a commonly used antihypertensive drug of class III BCS category. It suffers from the problem of poor intestinal absorption or permeability thus low bioavailability. The objective of the present study was to enhance the permeability of atenolol by using a suitable technique, which is economical and devoid of using any organic solvent.

Methods: The nanocrystal technology by high-pressure homogenization was chosen for this purpose, which is a less expensive and simple method. In this technique, no organic solvent was used. The study was further aimed to characterize prepared nanocrystals in the solid state by Fourier Transform Infrared Spectroscopy (FTIR), Powder X-Ray Diffraction (PXRD) patterns, particle size, zeta potential, %yield and drug permeation study through isolated goat’s intestine. An in-vivo study was carried out to determine the pharmacokinetic property in comparison to pure drug powder using rats as experimental animals. The formulation design was optimized by a 3(2) factorial design. In these designs, two factors namely surfactant amount (X1) and speed of homogenizer (X2) were evaluated on three dependent variables namely particle size (y1), zeta potential (y2) and production yield (y3).

Results: PXRD study indicated the presence of high crystal content in the prepared formulation. These nanocrystal formulations were found with a narrow size range from 125 nm to 652 nm and positive zeta potential of 16-18 mV. Optimized formulations showed almost 90% production yield. Permeability study revealed 90.88% drug release for optimized formulation in comparison to the pure drug (31.22%). The FTIR study also exposed that there was no disturbance in the principal peaks of the pure drug atenolol. This confirmed the integrity of the pure drug and its compatibility with the excipients used. A significant increase in the area under the concentration-time curve Cpmax and MRT for nanocrystals was observed in comparison to the pure drug. The higher values of the determination coefficient (R2) of all three parameters indicated the goodness of fit of the 3(2) factorial model. The factorial analysis also revealed that speed of homogenizer had a bigger effect on particle size (-0.2812), zeta potential (-0.0004) and production yield (0.0192) whereas amount of surfactant had a lesser effect on production yield (-370.4401), zeta potential (-43.3651) as well as particle size (-6169.2601).

Conclusion: It is concluded that the selected method of nanocrystal formation and its further optimization by factorial design was effective to increase the solubility, as well as permeability of atenolol. Further, the systematic approach of factorial design provides rational evaluation and prediction of nanocrystals formulation on the selected limited number of smart experimentation.

Keywords: Atenolol, nanocrystal, factorial design, ANOVA, antihypertensive, pharmacokinetic.

[1]
Fichera, M.A.; Keck, C.M.; Müller, R.H. Nanopure technology-drug nanocrystals for the delivery of poorly soluble drugs. In: Particles; , 2004. Orlando. 28.
[2]
Pace, G.W. Process to generate submicron particles of water insoluble compounds. 2001. US Patent 6-177-103.
[3]
Bushrab, N.F.; Müller, R.H. Nanocrystals of poorly soluble drags for oral administration. New Drugs, 2003, 5, 20-22.
[4]
Srivalli, K.M.R.; Mishra, B. Drug nanocrystals: A way toward scale-up. Saudi Pharmaceut. J., 2016, 24, 386-404.
[5]
Wander, G.S.; Chhabra, S.T.; Kaur, K. Atenolol drug profile. Suppl. JAPI., 2009, 57, 13-16.
[6]
Wu, F.; Cheni, P.; Lee, Y.J.; Long, R.R. Comparative pharmacokinetics of two atenolol products. J. Food Drug Anal., 2003, 1, 4-7.
[7]
Singh, B.; Kaur, S.; Chakkal, A.N. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology. AAPS PharmSciTech, 2006, 7, E19-E28.
[8]
Vaithiyalingam, S.R.; Sastry, S.V.; Dehon, R.H.; Reddy, I.K.; Khan, M.A. Long-term stability characterization of a controlled release gastrointestinal therapeutic system coated with cellulose acetate pseudolatex. Pharmazie, 2001, 56, 66-69.
[9]
Kim, J.; Shin, S.C. Controlled release of atenolol from the ethylene-vinyl acetate matrix. Int. J. Pharm., 2004, 273, 23-27.
[10]
Jug, M.; Bećirević-Laćan, M.; Bengez, S. Novel cyclodextrin-based film formulation intended for buccal delivery of atenolol. Drug Dev. Ind. Pharm., 2009, 35, 796-807.
[11]
Kulkarni, A.; Bhatia, M. Development and evaluation of regioselective bilayer floating tablets of atenolol and lovastatin for biphasic release profile. Iranian. J. Pharma. Res., 2009, 8, 15-25.
[12]
Srivastava, A.K.; Wadhwa, S.; Ridhurkar, D.; Mishra, B. Oral sustained delivery of atenolol from floating matrix tablets—formulation and in vitro evaluation. Drug Dev. Ind. Pharm., 2005, 31, 367-374.
[13]
Kobierski, S.; Hanisch, J.; Mauludin, R.; Müller, R.H.; Keck, C. Nanocrystal production by smart crystal combination technology. Int. Symp. Control. Rel. Bioact. Mater, 2008, 35, p. 3239.
[14]
Loh, Z.H.; Samanta, A.K.; Heng, P.W.S. Overview of milling techniques for improving the solubility of poorly water-soluble drugs. Asian J. Pharmaceut. Sci., 2015, 19, 255-274.
[15]
Merisko-Liversidge, E.; Liversidge, G.G.; Copper, E.R. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur. J. Pharma. Sci., 2003, 18, 113-120.
[16]
Akkar, A.; Müller, R.H. Nanocrystals of Itraconazole and amphotericin B produced by high pressure homogenisation.Annual Meeting of the American Association of Pharmaceutical Scientists. American Scientific Publishers, Valencia, USA, 2003, pp. 479-491.
[17]
Mauludin, R.; Möschwitzer, J.; Müller, R.H. Comparison of Ibuprofen drug nanocrystals produced by high pressure homogenization (HPH) versus ball milling AAPS Annual Meeting, Nashville, 2005, p. T2217.
[18]
Singh, A.; Deep, A. Formulation and evaluation of nanoparticles containing atenolol. Int. J. Pharm. Res., 2011, 3, 59-62.
[19]
Moneghini, M.; Carcano, A.; Zingone, G.; Perissutti, B. Studies in dissolution enhancement of atenolol. Int. J. Pharm., 1998, 175, 177-183.
[20]
Anwar, M.; Warsi, M.H.; Mallick, N.; Akhter, S.; Gahoi, S.; Jain, G.K.; Talegaonkar, S.; Ahmad, F.J.; Khar, R.K. Enhanced bioavailability of nano-sized chitosan–atorvastatin conjugate after oral administration to rats. Eur. J. Pharm. Sci., 2011, 44, 241-249.
[21]
Mummaneni, V.; Dressman, J.B.; Amidon, G.L. Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs. Pharmaceut. Res., 1995, 12, 780-786.
[22]
Vergote, G.J.; Vervaet, C. Van, Driessche, I.; Hoste, S.; De Smedt, S.; Demeester, J.; Jain, R.A.; Ruddy, S.; Remon, J.P. In-vivo evaluation of matrix pellets containing nanocrystalline ketoprofen. Int. J. Pharm., 2002, 240, 79-84.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 3
Year: 2020
Page: [306 - 315]
Pages: 10
DOI: 10.2174/2210681209666190220120053
Price: $25

Article Metrics

PDF: 11
HTML: 2